{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:35:33Z","timestamp":1793140533851,"version":"4.5.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Cutaneous immune-related adverse events (cirAEs) are associated with improved survival in tumor patients undergoing immune checkpoint inhibitors (ICIs) therapy, while inconsistent evidence has been reported across tumor subtypes. This study aimed to evaluate the association of cirAEs and their subtypes with cancer prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four databases including Cochrane Library, Embase, PubMed and Web of Science were searched for original publications from inception to April 30, 2024. A meta-analysis was carried out for overall survival (OS) and progression-free survival (PFS) of patients, and pooled hazard ratios (HRs) with 95% confidential intervals (CIs) were calculated. Subgroup analyses involving cirAEs subtype, cancer type, ICIs type, geographic region of patients, and study quality were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty-five studies comprising a total of 26817 patients with ICIs treatment were included in the study. The occurrence of cirAEs was associated with prolonged OS (HR, 0.54 [95%CI, 0.46-0.63];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and PFS (HR, 0.51 [95%CI, 0.43-0.60];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Favorable survival was observed in patients with vitiligo, with the most pronounced OS (HR, 0.23 [95%CI, 0.18-0.33];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and PFS (HR, 0.28 [95%CI, 0.21-0.38];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001). Similarly, the prolonged OS (HR, 0.69 [95%CI, 0.64-0.74];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) and PFS (HR, 0.69 [95%CI, 0.58-0.82];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) in patients with rash. Significant benefit in OS were also observed in drug hypersensitivity or eruption, eczematous, lichenoid or lichen planus-like lesion, pruritus and psoriasis, but not in bullous pemphigoid, maculopapular and mucositis. Favorable survival was observed in patients with RCC, NSCLC and MM, with the most pronounced OS (HR, 0.22 [95%CI, 0.08-0.59];\n                      <jats:italic>P<\/jats:italic>\n                      = 0.002) and PFS (HR, 0.22 [95%CI, 0.11-0.43];\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) for RCC patients; and only OS benefit in HNSCC (HR, 0.64 [95%CI, 0.42-0.99];\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). Subgroup analyses involving geographic region and study quality showed consistent results with the overall estimate confirming robustness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The occurrence of cirAEs, especially in vitiligo and rash, predicted a significant survival benefits among tumor patients receiving ICIs therapy, especially in MM, RCC and NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1689519","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:42Z","timestamp":1762492902000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Cutaneous adverse events associated with the efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (Icis): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-022-01325-0","article-title":"Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts","volume":"15","author":"Wang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: A systemic review and meta-analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","article-title":"Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis","volume":"18","author":"Zhou","year":"2020","journal-title":"BMC Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: A systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of fda-approved immune checkpoint inhibitors per nccn guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02803-5","article-title":"Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors","volume":"70","author":"Zhong","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyac009","article-title":"Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab","volume":"52","author":"Ueda","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae053","article-title":"Cancer type and histology influence cutaneous immunotherapy toxicities: A multi-institutional cohort study","volume":"191","author":"Wan","year":"2024","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040860","article-title":"Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"13","author":"Paderi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic nsclc treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00278-x","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: A retrospective multicohort study","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1038\/s41598-022-11128-5","article-title":"Cutaneous immune-related adverse events among Taiwanese cancer patients receiving immune checkpoint inhibitors link to a survival benefit","volume":"12","author":"Cho","year":"2022","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6449","article-title":"Immune-related adverse events and outcomes among pan-cancer patients receiving immune checkpoint inhibitors: A monocentric real-world observational study","volume":"12","author":"Ge","year":"2023","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: A systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad154","article-title":"Immune-related adverse events and clinical outcomes in advanced urothelial cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Sanda","year":"2023","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.030","article-title":"Development of Multiple Cutaneous Immune-Related Adverse Events among Cancer Patients after Immune Checkpoint Blockade","volume":"88","author":"Asdourian","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103376","article-title":"Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis","volume":"163","author":"Han","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02303-1","article-title":"Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma","volume":"68","author":"Abu-Sbeih","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02899-y","article-title":"Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-pd-1 therapy in real-world practice","volume":"145","author":"Ahn","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0550","article-title":"Association between skin reaction and clinical benefit in patients treated with anti-programmed cell death 1 monotherapy for advanced non-small cell lung cancer","volume":"25","author":"Aso","year":"2020","journal-title":"Oncologist"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16311","article-title":"Cutaneous adverse events: A predictor of tumour response under anti-pd-1 therapy for metastatic melanoma, a cohort analysis of 189 patients","volume":"34","author":"Bottlaender","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","article-title":"Correlations between the immune-related adverse events spectrum and efficacy of anti-pd1 immunotherapy in nsclc patients","volume":"20","author":"Cortellini","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.cllc.2020.06.010","article-title":"Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with nsclc with a pd-L1 expression \u2265 50% and their relationship with clinical outcomes","volume":"21","author":"Cortellini","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2023.101.08","article-title":"a real-world study on the incidence and outcome of immune-related adverse events in lung cancer patients","volume":"26","author":"Cui","year":"2023","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.09.002","article-title":"Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study","volume":"5","author":"Dousset","year":"2021","journal-title":"JAAD Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33780","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","journal-title":"Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.10.009","article-title":"Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients","volume":"89","author":"Fujisawa","year":"2018","journal-title":"J Dermatol Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.01.003","article-title":"Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"21","author":"Hosoya","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e186","article-title":"Characterization and prognostic significance of cutaneous adverse events to anti-programmed cell death-1 therapy","volume":"34","author":"Lee","year":"2019","journal-title":"J Korean Med Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2020.03.017","article-title":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors","volume":"132","author":"Maillet","year":"2020","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after pd-1\/pd-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.630136","article-title":"Immune-related adverse events are associated with clinical benefit in patients with non-small-cell lung cancer treated with immunotherapy plus chemotherapy: A retrospective study","volume":"11","author":"Morimoto","year":"2021","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12677","article-title":"Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy","volume":"7","author":"Nakamura","year":"2016","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15309","article-title":"Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study","volume":"47","author":"Nakano","year":"2020","journal-title":"J Dermatol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02536-5","article-title":"Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: A pooled exploratory analysis from a global cohort","volume":"69","author":"Naqash","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005493","article-title":"Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dmmr\/msi-H metastatic colorectal cancer","volume":"11","author":"Nasca","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000518619","article-title":"Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma","volume":"11","author":"Ng","year":"2022","journal-title":"Liver Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2805-3","article-title":"Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis","volume":"145","author":"Ricciuti","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e15747","DOI":"10.1111\/dth.15747","article-title":"Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma","volume":"35","author":"Shreberk-Hassidim","year":"2022","journal-title":"Dermatol Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (Iraes) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ecog-acrin E1609 study analysis","volume":"9","author":"Tarhini","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.01.022","article-title":"Patterns and prognostic significance of cutaneous immune-related adverse events in non-small cell lung cancer","volume":"147","author":"Thompson","year":"2021","journal-title":"Eur J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1186\/s12885-020-07508-7","article-title":"The association between immune-related adverse events and survival outcomes in asian patients with advanced melanoma receiving anti-pd-1 antibodies","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13241","article-title":"Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase ii study","volume":"108","author":"Yamazaki","year":"2017","journal-title":"Cancer Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.03.008","article-title":"Long-term survival of patients with non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy in real-world settings","volume":"23","author":"Yoneda","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1186\/s12885-022-10199-x","article-title":"Are anti-pd-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Cancer"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103285","article-title":"Association between immune-related adverse events and efficacy of pd-1 inhibitors in chinese patients with advanced melanoma","volume":"12","author":"Zhao","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00864","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world","volume":"41","author":"Kamangar","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708195","article-title":"Immune-related adverse events associated with outcomes in patients with NSCLC treated with anti-PD-1 inhibitors: a systematic review and meta-analysis","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1689519\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T05:21:44Z","timestamp":1762492904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1689519\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":67,"alternative-id":["10.3389\/fonc.2025.1689519"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1689519","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"article-number":"1689519"}}